Get informed when a big investor buys or sells
+ FollowLoading insider trades…
Loading congress trades…
| Market cap | $385,906.00 |
|---|---|
| Enterprise Value | $688,476.00 |
| Earnings per Share | $-0.01 |
| Beta | -6.96 |
| Outstanding Shares | 771,811,360 |
| P/E Ratio | -0.06 |
|---|---|
| PEG | 0.07 |
| Price to Sales | - |
| Price to Book Ratio | -0.0 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -2 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.44 |
| Debt to Equity | -0.14 |
No data
No data available for the latest quarter.
No data available for the latest quarter.
Actavia Life Sciences, Inc. operates as a biotechnology enterprise specializing in the development of therapeutic solutions aimed at treating various forms of leukemia and lymphoma. Additionally, the company is engaged in formulating sma...